Executive Summary
TSP-101 is an Fn14-targeting molecule in Phase 1, in-licensed from Tensegrity as part of argenx's strategy to bring in later-stage pipeline candidates from biopharma companies.
Tensegrity (TSP-101)
Fn14 ·
Target: Fn14
Full NameFibroblast Growth Factor-Inducible 14 (TWEAK receptor)
PathwayTWEAK/Fn14 signaling
Mechanism of Action
Target Biology[Corp '26 S22]
No target biology data available.
Clinical Data
No clinical trial data available.
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Phase 1 in 2026 | 2026 | medium | First-in-human safety and PK data | — |